Open/close main nav Menu Menu MYMETRO Collapse + - ER/URGENT CARE
MyMetro
  • Emergency Cross
    Emergency & Urgent Care

    Is this an Emergency?

    In an emergency, seconds count. If you are alarmed by unusually severe symptoms, seek immediate care. Please call 911 if you feel your condition is life threatening. If a poison is involved, please call Grand Rapids Poison Control Center at (800) 222-1222.

    When to go to the Emergency Room When to go to Urgent Care
  • Hospital ER
    NOW OPEN

    Emergency Room Hours:
    24 hours a day, 7 days a week

    • Directions to the ER

      5900 BYRON CENTER AVE SW

      WYOMING, MI

      (616) 252-7200

      ER map
  • Urgent Care

    Urgent Care Hours:
    Open 9 am - 9 pm, 7 days a week

    • Directions to Urgent Care

      4055 CASCADE RD SE

      GRAND RAPIDS, MI

      (616) 252-4010

      Urgent Care map
  • Clinical Trials

    Current Enrolling Trials

    For more information on any of the studies listed below, please e-mail research@metrogr.org.

    CANCER

    Condition: Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and Chronic Myelolymphocytic Leukemia (CMML)
    The purpose of the research is to determine the level of vitamin c (also known as ascorbic acid), in the blood from patients either on treatment or intending to receive treatment for MDS, AML, or CMML. We are curious if MDS, AML, or CMML patients are deficient in vitamin c-we think vitamin c may have an effect on some treatments for these diseases.
    Principal Investigator: Michael Zakem, DO
    Sponsor: Van Andel Research Institute (VARI)

    Metro Health – University of Michigan Health is also a member of the Cancer Research Consortium of West Michigan (CRCWM).  Visit www.crcwm.org for a listing of available clinical trials.

    NEURORADIOLOGY

    SMART – A prospective, multicenter registry assessing the embolization of neurovascular lesions using the Penumbra SMART COIL System
    Condition: Aneurysm, AVM (arterio-venous malformation), AVF (arterio-venous fistula) or other brain vessel malformation
    The purpose of this registry is to collect data on the “real world” experience of the Smart systems. The registry will be used to evaluate the effectiveness of these
    systems in treating aneurysms, including the amount of aneurysm filling, time of treatment and results of subject follow-up.
    Investigators: Augusto Elias, MD; Ravi Shastri, MD
    Find this study on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02729740?term=SMART&rank=1

    PERIPHERAL ARTERY DISEASE

    LUTONIX BTK
    Condition: Peripheral Artery Disease (PAD)
    The goal of this research is to learn more about the benefits of using the Lutonix Drug-Coated Balloon catheter (formerly, Moxy Drug-Coated Balloon catheter) and to gather more data to show it’s safe when treating people with narrowed leg blood vessels.
    Principal Investigator: Larry Diaz, MD
    Find this study on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT01870401?term=lutonix+btk&rank=1

    PRIME Registry
    Condition: Peripheral Artery Disease (PAD)
    The purpose of this research is to evaluate immediate and long-term outcomes of endovascular revascularization in patients with Critical Limb Ischemia (CLI) and advanced PAD.
    Principal Investigator: Larry Diaz, MD
    Find this study on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02786173?term=PRIME&rank=5

    HEART DISEASE

    Plexa Registry
    Condition: Fast or Irregular Heart Rhythms
    The purpose of this research is to confirm the long-term safety and reliability of the Plexa lead used with a BIOTRONIK ICD or CRT-D.
    Principal Investigator: Matthew Sevensma, DO
    Find this study on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03103503?term=plexa+registry&rank=1

     

joseph.weller@metrogr.org